

=> d his

(FILE 'HOME' ENTERED AT 21:08:16 ON 04 SEP 2007)

FILE 'REGISTRY' ENTERED AT 21:09:06 ON 04 SEP 2007

L1 STRUCTURE UPLOADED  
L2 0 S L1 SSS  
L3 19 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 21:09:38 ON 04 SEP 2007

L4 1 S L3

=> d bib abs

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:648488 CAPLUS

DN 141:173977

TI Preparation of substituted anilide ligands for the thyroid receptor  
IN Washburn, William N.; Meng, Wei; Ryono, Denis E.; Ellsworth, Bruce A.;  
Ericsson, Thomas; Rahimi-Ghadim, Mahmoud; Garg, Neeraj; Malm, Johan  
PA Bristol-Myers Squibb Company, USA; Karo Bio AB  
SO PCT Int. Appl., 96 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004067482	A2	20040812	WO 2004-US1985	20040123
	WO 2004067482	A3	20041021		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	US 2004180940	A1	20040916	US 2004-763878	20040123
	EP 1601641	A2	20051207	EP 2004-704944	20040123
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006516623	T	20060706	JP 2006-502986	20040123
PRAI	US 2003-442421P	P	20030124		
	WO 2004-US1985	W	20040123		
OS	MARPAT 141:173977				
GI					




AB Title compds. I [wherein X = O, Se, S, SO, SO<sub>2</sub>, CO, CH<sub>2</sub>, NH; R<sub>1</sub> = H, halo, CF<sub>3</sub>, alkyl; R<sub>2</sub> = halo, CF<sub>3</sub>, (cyclo)alkyl, (cyclo)alkenyl, alkynyl, (hetero)aryl(oxy), (cyclo)alkoxy, arylalkoxy, COR<sub>14</sub>, CR<sub>14</sub>(OR<sub>10</sub>)R<sub>15</sub>, NR<sub>14</sub>COR<sub>15</sub>, CONR<sub>14</sub>R<sub>15</sub>, NR<sub>14</sub>SO<sub>2</sub>R<sub>16</sub>, SO<sub>2</sub>NR<sub>14</sub>R<sub>15</sub>, SR<sub>16</sub>, SOR<sub>16</sub>, SO<sub>2</sub>R<sub>16</sub>, CH<sub>2</sub>NR<sub>14</sub>R<sub>15</sub>; R<sub>3</sub> = halo, alkyl; R<sub>5</sub> = H, halo, alkyl; R<sub>6</sub>, R<sub>7</sub> = independently H, halo, CN, (cyclo)alkyl; R<sub>8</sub>, R<sub>9</sub> = independently H, halo, alkoxy, OH, CN, CF<sub>3</sub>, alkyl; R<sub>10</sub> = independently H, alkyl; R<sub>11</sub> = CO<sub>2</sub>R<sub>14</sub>; R<sub>12</sub>, R<sub>13</sub> = independently H, halo, alkyl; R<sub>14</sub>, R<sub>15</sub> = independently H, (cyclo)alkyl, (hetero)aryl(alkyl); R<sub>16</sub> = independently (cyclo)alkyl, (hetero)aryl(alkyl); with provisos; and prodrugs, stereoisomers, and pharmaceutically acceptable salts thereof] were prepared as thyroid receptor ligands (no data). For example, 3-isopropyl-5-methylphenol was converted to 3-isopropyl-5-methyl-4-acetoxyphenol in a 3-step sequence. Bromination followed by iodination of 3-methyl-4-nitrophenol gave 3,5-dibromo-4-iodo-2-methylnitrobenzene, which was coupled with 3-isopropyl-5-methyl-4-acetoxyphenol to afford the di-Ph ether. Reduction of the nitro group to the amine using Fe in H<sub>2</sub>O/AcOH, followed by reductive amidation with Et malonyl chloride provided II. I or pharmaceutical compns. of I, alone or in combination with other therapeutic agents, are expected to be useful for preventing, inhibiting, or treating diseases or disorders associated with metabolic dysfunction or which are dependent upon the expression of a T<sub>3</sub> regulated gene (no data).

=> d 11

L1 HAS NO ANSWERS

L1 STR



G1 X, Ak

G2 H, X

G3 C, O, S, N, Se

41

Structure attributes must be viewed using STN Express query preparation.

=>